Innovent’s NDA Filing for Humira Biosimilar Accepted in China

Published on: November 13, 2018
Author: Amy Liu

Innovent Biologics of Suzhou reported that China regulators have accepted its filing of a new drug application for IBI303, a biosimilar to Humira (adalimumab). It is Innovent’s second NDA accepted by the NMPA — the first is its anti-PD-L1 candidate (IBI308).  IBI303 is a recombinant human anti-TNF-α monoclonal antibody aimed at ankylosing spondylitis (AS), rheumatoid arthritis (RA) and psoriasis. Innovent said IBI303 will offer a high-quality and affordable alternative to branded Humira in China.

Source: China Biotoday

Biotechnology Genomics Healthcare Services Life Science Medical Device Pharmaceutical